Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Volume

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Aug 20, 2021 10:33am

146 Views

Post# 33739432

RE:Volume

Maybe you should try and force yourself to say something positive about the stock every one and a while just so we can be sure you ae not about to do any harm to yourself!

But you are right on this one. How is this even possible? When the company was much smaller and had not possibility of being involved in large markets like NASH and cancer, I don't think this ever happened. But maybe our mystery seller is finally finished what they had to sell.